New Trade Alert: Nemaura Medical Inc. (NASDAQ: NMRD)

 
info@mybeststockpicks.com 1-(844)-30-STOCK  
To Get Update On Mobile Text STOCKS to 67076
The #1 Newsletter for Highly Profitable Penny Stock Alerts
Our new PIck is NMRD
Hello!
 

New Trade Alert: Nemaura Medical Inc. (NASDAQ: NMRD)

Today we would like to bring to your attention NMRD, which we first presented to you earlier in July. 

Since our last alert, NMRD has rallied upwards of 13% to a high of 3.28.

Since this rally NMRD has consolidated below its 20 day moving average. In the event that it breaks out above and sustains these levels, once again this could present increased upside potential.

Additionally, if NMRD continues to hold above its low seen two weeks ago, this could present increased opportunity.

As a reminder, NMRD is a “medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible glucose monitoring system for adjunctive use by persons with diabetes.”

This disruptive “patent-protected technology” has “the potential to greatly expand glucose monitoring to all persons with diabetes, including the 75% of diabetics who do not inject insulin.”

Diabetes is a global pandemic affecting more than 400 million people globally including 30 million people in the U.S.

According to Frost & Sullivan, the diabetes monitoring market is currently valued at $10.71 billion, and is forecasted to grow at a compound annual growth rate of 5.4% to reach $14.68 billion in 2022.

People suffering from diabetes are at a higher risk of premature death, heart attack, stroke, blindness, amputations and nerve damage. It is therefore little surprise diabetes is one of the biggest health challenges.

Having diabetes requires monitoring your blood sugar to avoid potential health complications. The most common method of measuring blood sugar is the A1C blood test which determines the average glucose level over the past 90 days, as well as a “point in time” glucose measurement. However, neither of these methods provide a continuous real-time measurement.

“SugarBEAT® consists of a daily disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings every five minutes.”

According to the company’s website, “BEAT™ technology will allow for remote continuous monitoring of chronic diseases and health conditions”, “allowing both users and healthcare professionals to closely monitor chronic diseases.”

Recently, NMRD announced its “Recent Highlights and Accomplishments”:

  • “Entered into a definitive collaboration agreement with Dallas Burston Ethitronix (DBE) to commercialize sugarBEAT® in the European Economic Area (EEA).
  • In preparation for commercial launch of sugarBEAT®, the company began expansion into new manufacturing facilities, enabling large scale production of its proprietary sensor technology.
  • Promoted Bashir Timol from Director of Strategy & Corporate Development to Chief Business Officer”

Since our last alert, NMRD has released the following developments:

Nemaura Places SugarBEAT® Manufacturer Order for UK Commercial Launch

LOUGHBOROUGH, England–(BUSINESS WIRE)–

Nemaura Medical Inc. (NMRD), a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use by persons with diabetes, today announced it has placed an initial order with its designated UK-based contract manufacturer for 12,500 sugarBEAT® rechargeable transmitters, which will be supplemented with approximately 100,000 skin-patches per month, also manufactured in the UK, in preparation for the anticipated sugarBEAT® product launch in the coming months.

SugarBEAT® consists of a daily-disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings at five minute intervals, and is expected to launch initially in the United Kingdom, upon CE Mark approval.

Dr Faz Chowdhury, CEO and chair of Nemaura Medical commented ‘We expect this initial order will support the successful launch of sugarBEAT® in the UK later this year, and also develop the capacities needed for subsequent scale up and launch in other countries which accept the CE Mark.’

Nemaura Medical recently completed a sugarBEAT® European three-stage clinical trial program consisting of 75 patients over 525 patient days in total, and have used this data to support their CE Mark application. A predecessor sugarBEAT® device, based on a wired wrist-watch form factor, received CE Mark approval in 2016.

NMRD presents a potentially compelling trade opportunity, which could continue to attract increased interest from Wall Street as more investors become familiar with the company.

However, don’t take our word for it, make sure to do your own due diligence.

Source: PR1, PR2WHOScientistWebsiteChart

 
 

 
Trading Rules [Please Review Before Taking Any Action]:
  1. Do not invest more than you are willing to lose. No one likes to consider the worst case, but it’s always a risk that exists. Rule of thumb – if you cannot sleep at night as a consequence of your investment, then you have over invested.
  2. Keep calm. Do not chase. Decide for yourself if you like the trade. If you are not comfortable with the perceived risks, stay out. Timelines are to be decided by you. Approach methodically, and seek technical confirmation for direction. Always trade with a strategy in mind.
  3. Never use market orders. Only use buy and sell limit orders. Protecting your investment is more important than missing gains. Use “trailing stop %” or “trailing stop $” orders. Personally I prefer mental stops while actively managing trades rather than entering your stop into your brokerage account.
  4. Cut losses quickly when day/swing trading. It’s better to acknowledge being wrong than to have false hope. Sometimes you will be wrong in doing so, often times it will save you. It all depends on your entry.
  5. Actively manage all your investments & trade during market hours only.Trading during pre/post market hours carries greater volatility/risk.

 

 

Don’t forget to try our Free Easy-to-Use SMS service for real-time alerts and winning tips. Simply send the message STOCKS to the number 67076.

 

Best Regards,

 

 

 

DISCLAIMER

The disclaimer is to be read and fully understood before using our site Mybeststockpicks.com also refered to as MBSP. This report/release/video profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. Never invest in any stock discussed on Mybeststockpicks.com or MBSP’s newsletter unless you can afford to lose your entire investment. Never listen to anyone on MBSP message boards or private messages sent by any user or member who offers any sort of financial advice. Please consult with a certified financial advisor before making any investment decisions. MBSP and any affiliates and information providers make no implied or expressed warranties on the information provided. Please verify quotes with your investment manager before making investment decisions. This is not to be construed as a solicitation to buy or sell securities. Any stock or featured companies on MBSP web site and/or newsletter involves a high degree of risk and volatility, and all investors should know that they may lose a portion or all of their investment if they decide to purchase any stock mentioned or talked about on MBSP or message boards. MBSP makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or members and does not guarantee the correctness, completeness or quality of information and statements presented on MBSP. Any such information or statements should be deemed apocryphal and opinions only. Neither MBSP, nor any of its affiliates, are registered investment advisors or broker dealers and do not make recommendations to buying, holding, or selling of any securities. MBSP simply provides a starting point for site members and viewers to compare their own thoughts against those here on the message boards at MBSP. The onus is on site members and viewers to complete their own due diligence. MBSP members and viewers should always make their own financial decisions. The accuracy and completeness of the information within any report, newsletter or on website message boards is only as reliable as the information that is provided by MBSP members and users. MBSP does not verify the information, and makes no warranty that the information is accurate. MBSP members, readers and viewers are cautioned that small and micro-cap stocks are high-risk investments and that all investment dollars can be lost. We suggest you consult a professional investment advisor before purchasing any stock. All opinions and postings expressed on MBSP web site are the opinions of MBSP members and users . All information concerning any company is provided by the members and users that create the information box on each board. MBSP recommends you use the information found here on the site and boards as an initial starting point for conducting you own research and conduct your own due diligence (also known as “DD” on any company you read about here at MBSP, in order to determine your own personal opinion of the company before investing in these or any other companies. MBSP assumes all information to be truthful and reliable. However, we cannot and do not warrant or guarantee the accuracy of this information. MBSP is NOT an Investment Advisor, Financial Planning Service or a Stock Brokerage Firm and in accordance with such MBSP is not offering investment advice or promoting any investment strategies. MBSP is not offering securities for sale or solicitation of any offer to buy or sell securities. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. On occasion, MBSP may receive compensation from a third party in relation to the companies being profiled in its Newsletters sent to our members. In such a case MBSP directly mentions such compensations at the bottom of this disclaimer along with the exact form and amount of compensation.  in relation to the companies being profiled in its Newsletters sent to our members. In such a case MBSP directly mentions such compensations at the bottom of this disclaimer along with the exact form and amount of compensation.  Mybeststockpicks.com has been compensated total of two thousand dollars by ALG LLC to perform  a two day investors awareness advertisement on NMRD Do your own research and due diligence before investing in any company. MBSP merely is providing information and is in no way or manner suggesting an investment in any company or investment opportunity. You are the investor and are making decisions for yourself. report/release/video profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.

 

2012 www.mybeststockpicks.com. All rights reserved.
Total Views: 309 ,